Health care legislation firm Frier Levitt has analyzed FDA enforcement steps against “analysis only” peptide suppliers. Their summary: the FDA considers an item’s classification based on its intended use, not its disclaimers. When Sites include things like dosage guides, reconstitution Guidance, or link to forums discussing human use, the “